3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
8
Phase 2
8
Phase 4
2
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
4
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Weight Loss
1
Sleep Initiation and Maintenance Disorders
1
Protein Deficiency
1
Prostatic Neoplasms
1
Prolactinoma
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Malnutrition
1
Kidney Neoplasms
1
Iron Deficiencies
1
Hemostasis
1
Delirium
1
Carcinoma, Renal Cell
1
Anemia
1
Interventions
Zoledronic Acid
5
Bevacizumab
3
exemestane
2
Therapeutics
2
Standard of Care
2
Pamidronate
2
Oxaliplatin
2
Misoprostol
2
Magnetic Resonance Spectroscopy
2
Letrozole
2
Ibandronic Acid
2
Fulvestrant
2
Fluorouracil
2
Cetuximab
2
Capecitabine
2
vandetanib
1
palbociclib
1
liposomal doxorubicin
1
huaier
1
eribulin
1
enzalutamide
1
darolutamide
1
cabozantinib
1
aldesleukin
1
abemaciclib
1
Vindesine
1
Trastuzumab
1
Sugars
1
Stents
1
Specimen Handling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 4
×
Neoplasm Metastasis
×
Standard of Care
×
Clear all
NCT01468623
2023-07-19
PROFUSE
Myriad Genetic Laboratories, Inc.
Phase 4
Terminated
51 enrolled
NCT01129336
2014-05-20
MACS1295
Novartis
Phase 4
Completed
44 enrolled
10 charts